Other Information.
+Added: (a) The information
+Added: set forth in Note 11 (Subsequent Events) regarding the May 11, 2026 filing of the civil action against alleged naked short sellers
Insider Trading Plans
−Removed: During the quarter ended December 31, 2025, no director
+Added: During the quarter ended March 31, 2026, no director
or Section 16 officer adopted , modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
3 unchanged sentences
(incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 28, 2025)
+Added: Agreement and Plan of Merger, dated as of April 27, 2026, by and among Lunai Bioworks, Inc., Lunai Bioworks IP, Inc., Neurobridge IP Holdings Incorporated, Oncotelic Inc., and Pelerin Therapeutics Inc.
+Added: (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on April 29, 2026).ertificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024)
Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024)
Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to Form 8-K filed with the SEC on May 24, 2024)
+Added: Certificate of Designation of Series B Convertible Preferred Stock of Lunai Bioworks, Inc., as filed with the Secretary of State of the State of Delaware on May 1, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on May 5, 2026).
Employment Agreement by and between Nathen Fuentes and Renovaro Inc., dated as of January 6, 2025.
1 unchanged sentence
Form of Exchange Agreement (incorporated herein by reference to Exhibit 99.1 to Form 8-K filed with the SEC on July 9, 2025)
+Added: Form of Debt Exchange Agreement, dated as of March 24, 2026, between Lunai Bioworks, Inc.
+Added: and certain Holders (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 30, 2026).
+Added: Form of Common Stock Purchase Warrant, dated as of March 24, 2026, issued by Lunai Bioworks, Inc.
+Added: (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on March 30, 2026).
+Added: Securities Purchase Agreement, dated as of November 24, 2025, between Lunai Bioworks, Inc.
+Added: and the Investor named therein (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on November 24, 2025).
+Added: At-the-Market Sales Agreement, dated as of December 2, 2025, between Lunai Bioworks, Inc.
+Added: and Dawson James Securities, Inc.
+Added: (incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K filed with the SEC on December 3, 2025).
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
8 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase
+Added: Cover Page Interactive Data File (formatted as Inline XBRL and contained
+Added: in Exhibit 101)
Filed herewith.
4 unchanged sentences
undersigned, thereunto duly authorized.
−Removed: February 17, 2026
LUNAI BIOWORKS INC.
8 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.